This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Verde AgriTech Ltd has announced significant drilling results from the Alto da Serra target, part of the Man of War project, completing a total of 3,640 meters of drilling across three targets [1][2][3] Drilling Results - Key results from the latest drilling assays include: - 13,944 ppm Total Rare Earth Oxides (TREO) and 5,222 ppm Magnetic Rare Earth Oxides (MREO) from AP-AD-06 [2] - 4,321 ppm TREO and 1,004 ppm MREO from AP-AD-08 over 61 meters [2] - 213 ppm Dysprosium and Terbium (DyTb) from AP-ND-01 [2] - The project consists of three exploration targets: Nau de Guerra, Bálsamo, and Alto da Serra, all showing significant rare earth elements presence [2][3] Strategic Importance - The concentrations of magnetic and heavy rare earths in the Man of War project are crucial as industries seek alternatives to China's dominance in rare earths, enhancing the project's potential to meet high-tech sector demands [3] Mineralization and Recovery Potential - The Alto da Serra target exhibits high concentrations of valuable rare earth elements with favorable mineralization continuity and depth, supporting efficient extraction and processing [6][7] - The significant thickness of mineralized zones across drill holes enhances recovery potential and opens opportunities for cost-effective operations [6] Quality Assurance in Analysis - Sampling and analysis protocols were executed with meticulous attention to ensure accuracy and consistency, with samples collected using a diamond drill rig and analyzed at SGS Laboratory [7] - Quality assurance and quality control (QA/QC) standards were upheld, including inter-laboratory verification at ALS Laboratory [7] Future Developments - Verde has commissioned a mineral resource report to be completed in compliance with NI 43-101 and Australian JORC standards [8]

Core Viewpoint - Mereo BioPharma Group plc is actively engaged in the development of innovative therapeutics for rare diseases and is participating in the Jefferies London Healthcare Conference to discuss its progress and future plans [1]. Company Overview - Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases, with two main product candidates: setrusumab for osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) [3]. - The partnership with Ultragenyx Pharmaceutical includes potential milestone payments of up to $245 million and royalties on commercial sales in Ultragenyx territories, while Mereo retains EU and UK commercial rights [3]. - Setrusumab has received orphan designation from both the EMA and FDA, along with several designations aimed at expediting its development [3]. - Alvelestat has also received U.S. Orphan Drug Designation and Fast Track designation from the FDA, with alignment on primary endpoints for a Phase 3 pivotal study [3]. - In addition to rare disease programs, Mereo is developing two oncology product candidates, etigilimab and navicixizumab, with ongoing clinical studies [3]. Upcoming Events - Dr. Denise Scots-Knight, CEO of Mereo BioPharma, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on November 19, 2024, at 10:30 am ET / 03:30 pm GMT [1][2]. - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for two weeks post-event [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA GROUP PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable Ordinary Shares ...

Exhibit 99.1 Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 London, November 12, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and ...

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equi ...

SINGAPORE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) (OTCQX: “VNPKF”) (“Verde” or the “Company”) is pleased to announce new significant results from its ongoing work to evaluate the presence of rare earths in historical diamond core drilling. The Company has completed the reassaying of 3,640 meters across three distinct targets previously drilled for phosphate. On October 07, 20241, Verde disclosed results for 743 meters from the Nau de Guerra target, and today it announces results f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA GROUP PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable Ordinary Shares, nom ...

Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 London, August 13, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage ...

Participants in the offering include new investors Frazier Life Sciences, Deerfield Management, and Perceptive Advisors, and existing Mereo shareholders, including Rubric Capital Management, Rock Springs Capital, and Janus Henderson Investors along with other leading healthcare-focused institutional investors. A shelf registration statement on Form S-3 (File No. 333-279433) relating to the offering of the ADSs described above was declared effective by the Securities and Exchange Commission ("SEC") on May 22 ...